Science

Emre Yekedüz: Adding 6 months of ADT to SBRT significantly improved clinical PFS compared to SBRT alone

lifelinecelltech.com

Mar 7, 2025, 03:20

Emre Yekedüz: Adding 6 months of ADT to SBRT significantly improved clinical PFS compared to SBRT alone

Emre Yekedüz, Associate Professor of Medical Oncology at Ankara University, shared an article by Giulia Marvaso, et al. on X:

“In patients with metachronous oligorecurrent hormone-sensitive Prostate Cancer, adding 6 months of ADT to SBRT significantly improved clinical progression-free survival compared to SBRT alone!

Phase 2, randomized trial.
105 patients, single-center (European Institute of Oncology, Milan).
SBRT (30 Gy/3 fx) ± 6 months ADT.”

ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial.

Authors: Giulia Marvaso, et al.

Emre Yekedüz: Adding 6 months of ADT to SBRT significantly improved clinical PFS compared to SBRT alone

Ankara University cancer Emre Yekedüz European Institute of Oncology fight against cancer Giulia Marvaso Global fight against cancer MedOnc OncoDaily Oncology prostate cancer SBRT

Cancer Center Near Me: Dana-Farber Cancer Institute

FDA Approves Nivolumab and Ipilimumab for First-Line Treatment of Unresectable Hepatocellular Carcinoma Based on CheckMate-9DW Trial

John Cena Announces He Overcame Skin Cancer Twice, Advocates for Sun Safety

William N. Hait to Receive 2025 AACR-Margaret Foti Award for Leadership in Cancer Research

Stella Kyriakides joins ESO as Co-Chair and Senior Lecturer in Cancer Policy to Guide the 2026–2028 Strategic Plan